Development Center for Biotechnology

Dcb-usa LLC

Shao-Zheng Peng

Chu-Bin Liao

Shih-Chieh Yen

Mann-Yan Kuo

Hung-Jyun Huang

Yuan-Ting Cho

Nan-Horng Lin

Hung-Kai Chen

Chen-Hsuan Ho

Yu-Chih Pan

Pao-Chiung Hong

Shian-Yi Chiou

Yi-Mei Chang

A compound, which can act as inhibitors of protein kinases, especially Class III RTKs such as FLT3, PDGFRα, c-KIT and/or CSF-1R kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a binder of a Proteolysis-Targeting Chimera (PROTAC) thereof. The compound can be used in the treatments of diseases or conditions mediated by FLT3, PDGFR, c-KIT, and/or CSF-1R kinases, or mediated by a mutant kinase of FLT3, PDGFR, c-KIT, and/or CSF-1R kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.

Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitors

A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein L is NRor O; R, R, R, R, R, Rand Rare defined herein. Compounds of formula (I) are useful for inhibition of protein kinases. Methods of using compounds of formula (I), stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Quinoxaline compounds, method for preparing the same and use thereof

A compound, capable of inhibiting kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The compound can be used in the treatments of diseases or conditions mediated by CSF-1R, c-KIT, FLT3, or PDGFR kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.

Quinoxaline compounds as type III receptor tyrosine kinase inhibitors

A regioselective one-step process for the synthesis of 2-hydroxyquinoxaline of Formula (1) or tautomers thereof: comprising reacting 1,2-phenylenediamine of Formula (2): with an excess amount of glyoxylic acid, glyoxylic acid monohydrate, or a 2,2-dialkoxyacetic acid of Formula (3): at a low temperature;wherein Rand Rare as defined in the specification.

Regioselective one-step process for synthesizing 2-hydroxyquinoxaline

A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein G is a heteroaryl, heterocyclic or alkyne; X is N or CH; Lis &#x2014;N(R)&#x2014;, &#x2014;O&#x2014;, &#x2014;C(S)&#x2014;, &#x2014;C(O)&#x2014;, or &#x2014;S&#x2014;; Lis &#x2014;N(R)&#x2014; or &#x2014;O&#x2014;; Rand Rare independently hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxy, C-Calkoxy, C-Calkoxy C-Calkoxy, N,N&#x2014;(C-Cdialkyl)amino C-Calkoxy, N&#x2014;(C-Calkyl)amino C-Calkoxy, C-Calkanoyl, C-Calkanoyloxy, N&#x2014;(C-Calkyl)amino, N,N&#x2014;(C-Cdialkyl)amino, C-Calkanoyl amino, or heterocyclyl, wherein C-Calkyl is optionally substituted with one or more substituents selected from fluorine and chlorine; R, Rand Rare independently hydrogen, fluorine or chlorine; Ris C-Calkyl or aryl, which is optionally substituted with one or more substituents selected from halogen, hydroxyl, amino, cyano, nitro; or Rand Rform a 5-6 membered cyclyl or heterocyclyl.

Quinazoline compounds, method for preparing the same and use thereof

Growing community of inventors

Taipei, Taiwan

Shao-Zheng Peng